SCHEMBL25647777

SCHEMBL25647777

COc1ccc(CNc2nccc3c2c(I)nn3[C@@H]2C=CC[C@@H](C(=O)OCc3ccccc3)C2)c(OC)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.38
▸ ALDH1A1 P00352 9/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ POLB P06746 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ CYP1A2 P05177 7/20 0.35
▸ CYP3A4 P08684 7/20 0.35
▸ CYP2C19 P33261 7/20 0.35
▸ TSHR P16473 6/20 0.35
▸ CYP2D6 P10635 5/20 0.35
▸ CYP2C9 P11712 5/20 0.35
▸ HSD17B10 Q99714 4/20 0.35
▸ TDP1 Q9NUW8 3/20 0.35
▸ HIF1A Q16665 2/20 0.35
▸ KDM4C Q9H3R0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31125830 1.00 MAPT (0.38) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL25270502 0.90 KDM4C (0.38) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL30497641 0.90 KDM4C (0.38) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL30449584 0.86 BTK (0.38) HDAC1
SCHEMBL25647778 0.83 TPH1 (0.34) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL30449660 0.82 BTK (0.40) —
SCHEMBL25227405 0.82 BTK (0.40) —
SCHEMBL24651144 0.76 NPC1 (0.43) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL30963348 0.74 KDM4C (0.39) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL25230106 0.73 KMT2A (0.42) MAPTALDH1A1MEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4634184-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY Crossfire Oncology Holding B.V. (NL) 2025-10-22 — — EP disclosed
US-20250074911-A1 MACROCYCLIC BTK INHIBITORS CROSSFIRE ONCOLOGY HOLDING B.V. (NL) 2025-03-06 — — US disclosed
EP-4448521-A1 REVERSIBLE MACROCYCLIC KINASE INHIBITORS Crossfire Oncology Holding B.V. (NL) 2024-10-23 — — EP disclosed
EP-4448523-A1 MACROCYCLIC BTK INHIBITORS Crossfire Oncology Holding B.V. (NL) 2024-10-23 — — EP disclosed
WO-2024126617-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY CROSSFIRE ONCOLOGY HOLDING B.V. (NL) 2024-06-20 — — WO disclosed
WO-2023110970-A1 MACROCYCLIC BTK INHIBITORS NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) 2023-06-22 — — WO disclosed
WO-2023110936-A1 REVERSIBLE MACROCYCLIC KINASE INHIBITORS NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) 2023-06-22 — — WO disclosed
WO-2023110936-A1 REVERSIBLE MACROCYCLIC KINASE INHIBITORS NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074911-A1 MACROCYCLIC BTK INHIBITORS BTK, LYN, LCK MAPT 4132/4885ALDH1A1 4774/4885MEN1 2453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback